Search Results - "Fury, Matthew"

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial by Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, Fury, Matthew G

“…Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy…”
Get full text

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review by Laurie, Scott A, Dr, Ho, Alan L, MD, Fury, Matthew G, MD, Sherman, Eric, MD, Pfister, David G, Prof

“…Summary Adenoid cystic carcinomas (ACC) are rare cancers usually arising in the salivary glands. Once metastatic, the natural history can vary; some patients…”
Get full text

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial by Migden, Michael R, Khushalani, Nikhil I, Chang, Anne Lynn S, Lewis, Karl D, Schmults, Chrysalyne D, Hernandez-Aya, Leonel, Meier, Friedegund, Schadendorf, Dirk, Guminski, Alexander, Hauschild, Axel, Wong, Deborah J, Daniels, Gregory A, Berking, Carola, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G, Rischin, Danny

“…Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous…”
Get full text

Survival with Cemiplimab in Recurrent Cervical Cancer by Tewari, Krishnansu S, Monk, Bradley J, Vergote, Ignace, Miller, Austin, de Melo, Andreia C, Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A, Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Guerra Alía, Eva M, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Mathias, Melissa, Fury, Matthew G, Oaknin, Ana

“…Cervical cancer that relapses after platinum-containing chemotherapy is often refractory to salvage therapy. Cemiplimab, a fully human antibody to PD-1, was…”
Get full text

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma by Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G., Rischin, Danny

“…A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients…”
Get full text

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 by Falchook, Gerald S., Leidner, Rom, Stankevich, Elizabeth, Piening, Brian, Bifulco, Carlo, Lowy, Israel, Fury, Matthew G.

“…BackgroundBasal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors…”
Get full text

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer by Rischin, Danny, Gil-Martin, Marta, González-Martin, Antonio, Braña, Irene, Hou, June Y., Cho, Daniel, Falchook, Gerald S., Formenti, Silvia, Jabbour, Salma, Moore, Kathleen, Naing, Aung, Papadopoulos, Kyriakos P., Baranda, Joaquina, Fury, Wen, Feng, Minjie, Stankevich, Elizabeth, Li, Jingjin, Yama-Dang, N. Alice, Yoo, Suk-Young, Lowy, Israel, Mathias, Melissa, Fury, Matthew G.

“…To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT)…”
Get full text

Letter to the Editor on “Medical School or Provider School” by Bernstein, David N., Fury, Matthew S.

Get full text

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing by Rischin, Danny, Migden, Michael R, Lim, Annette M, Schmults, Chrysalyne D, Khushalani, Nikhil I, Hughes, Brett G M, Schadendorf, Dirk, Dunn, Lara A, Hernandez-Aya, Leonel, Chang, Anne Lynn S, Modi, Badri, Hauschild, Axel, Ulrich, Claas, Eigentler, Thomas, Stein, Brian, Pavlick, Anna C, Geiger, Jessica L, Gutzmer, Ralf, Alam, Murad, Okoye, Emmanuel, Mathias, Melissa, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G, Guminski, Alexander

“…BackgroundCemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase…”
Get full text

PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma by Schoder, Heiko, Fury, Matthew, Lee, Nancy, Kraus, Dennis

“…In the Western world, more than 90% of head and neck cancers are head and neck squamous cell carcinomas (HNSCCs). The most appropriate treatment approach for…”
Get full text

Biomechanical Characteristics of Ulnar Collateral Ligament Injuries Treated With and Without Augmentation: A Network Meta-analysis of Controlled Laboratory Studies by Kunze, Kyle N., Fury, Matthew S., Pareek, Ayoosh, Camp, Christopher L., Altchek, David W., Dines, Joshua S.

“…Background: Treatment of ulnar collateral ligament (UCL) tears with suture tape augmentation has gained interest given preliminary reports of favorable…”
Get full text

Double-Row Repair With Platelet-Rich Plasma Optimizes Retear Rates After Small to Medium Full-Thickness Rotator Cuff Repair: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials by Lavoie-Gagne, Ophelie, Fury, Matthew S., Mehta, Nabil, Harkin, William E., Bernstein, David N., Berlinberg, Elyse J., Parvaresh, Kevin, O’Donnell, Evan, Forsythe, Brian

“…To compare the different interventions described in the literature for the surgical treatment of small and medium complete rotator cuff tears. A systematic…”
Get full text

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies by Papadopoulos, Kyriakos P, Johnson, Melissa L, Lockhart, Albert C, Moore, Kathleen, Falchook, Gerald S, Formenti, Silvia C, Naing, Aung, Carvajal, Richard D, Rosen, Lee S, Weiss, Glen J, Leidner, Rom S, Li, Jingjin, Paccaly, Anne, Feng, Minjie, Stankevich, Elizabeth, Lowy, Israel, Fury, Matthew G, Crittenden, Marka R

“…This first-in-human study assessed the safety, tolerability, dose-limiting toxicities (DLT), antitumor activity, and pharmacokinetics of cemiplimab, a…”
Get full text

Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561–2572 (2022) by Ge, Wenzhen, Chen, Chieh, Wu, Ning, Fury, Matthew G, Ruiz, Emily, Jalbert, Jessica J

Get full text

A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma by Dunn, Lara A., Riaz, Nadeem, Fury, Matthew G., McBride, Sean M., Michel, Loren, Lee, Nancy Y., Sherman, Eric J., Baxi, Shrujal S., Haque, Sofia S., Katabi, Nora, Wong, Richard J., Xiao, Han, Ho, Alan L., Pfister, David G.

“…Activation of the PI3K/mTOR signaling pathway is common in head and neck squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is…”
Get full text

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort by Segal, Neil H., Ou, Sai-Hong I., Balmanoukian, Ani, Fury, Matthew G., Massarelli, Erminia, Brahmer, Julie R., Weiss, Jared, Schöffski, Patrick, Antonia, Scott J., Massard, Christophe, Zandberg, Dan P., Khleif, Samir N., Xiao, Feng, Rebelatto, Marlon C., Steele, Keith E., Robbins, Paul B., Angra, Natasha, Song, Xuyang, Abdullah, Shaad, Butler, Marcus

“…Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging clinical activity and manageable safety…”
Get full text

Change in humeral anchor position significantly affects isometry in ulnar collateral ligament repair: a 3-dimensional computer modeling study by Fury, Matthew S., Liu, Tianyu, Cai, Wenli, O’Donnell, Evan A., Oh, Luke S.

“…Medial ulnar collateral ligament (UCL) repair utilization is increasing in recent years, bolstered by shorter rehabilitation and satisfactory clinical…”
Get full text

Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer by Koutcher, Lawrence, M.D, Sherman, Eric, M.D, Fury, Matthew, M.D., Ph.D, Wolden, Suzanne, M.D, Zhang, Zhigang, Ph.D, Mo, Qianxing, Ph.D., M.S, Stewart, Laschelle, B.A, Schupak, Karen, M.D, Gelblum, Daphna, M.D, Wong, Richard, M.D, Kraus, Dennis, M.D, Shah, Jatin, M.D, Zelefsky, Michael, M.D, Pfister, David, M.D, Lee, Nancy, M.D

“…Purpose To compare concurrent cisplatin (CDDP) and radiation (RT) with cetuximab (C225) and RT for locally advanced head-and-neck cancer (LAHNC). Methods and…”
Get full text

18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma by Lim, Remy, Eaton, Anne, Lee, Nancy Y, Setton, Jeremy, Ohri, Nisha, Rao, Shyam, Wong, Richard, Fury, Matthew, Schöder, Heiko

“…Treatment of oropharyngeal squamous cell carcinoma with chemoradiotherapy can now accomplish excellent locoregional disease control, but patient overall…”
Get full text

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer by Sherman, Eric J., Dunn, Lara A., Ho, Alan L., Baxi, Shrujal S., Ghossein, Ronald A., Fury, Matthew G., Haque, Sofia, Sima, Cami S., Cullen, Grace, Fagin, James A., Pfister, David G.

“…BACKGROUND Patients with recurrent and/or metastatic, radioactive iodine‐refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase…”
Get full text